Business
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
CARLSBAD, Calif., May 14, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, in a fireside chat hosted by Joseph Pantginis, Ph.D., Managing Director, Equity Research, on Tuesday, May 20, 2025, at 2:30pm ET. The 3rd Annual
About this update from Lineage Cell Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1740,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/0edff1e28a57af228632f00c724aa67e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0TNM4vhBCwwHcVptArNivw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0edff1e28a57af228632f00c724aa67e","width":960,"height":199},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.s_02cpFthbXFLQgLNI3qA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/0edff1e28a57af228632f00c724aa67e","width":1200,"height":248}},"lazy":false},{"type":"text","content":"CARLSBAD, Calif., May 14, 2025--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, in a fireside chat hosted by Joseph Pantginis, Ph.D., Managing Director, Equity Research, on Tuesday, May 20, 2025, at 2:30pm ET. The 3rd Annual H.C. Wainwright BioConnect Investor Conference takes place on Tuesday, May 20, 2025, at the Nasdaq stock exchange headquarters in New York, NY.","length":660,"tagName":"p"},{"type":"text","content":"Investors interested in scheduling an in-person meeting with the Lineage management team should contact their H.C. Wainwright representative or email [email protected]. A replay of Lineage’s fireside chat will be available on the Events and Presentations section of Lineage’s website, following the conclusion of the conference.","length":329,"tagName":"p"},{"type":"text","content":"About Lineage Cell Therapeutics, Inc.","length":37,"tagName":"p"},{"type":"text","content":"Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, "off-the-shelf," cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functi...